mechlorethamine has been researched along with Lung Diseases in 28 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Lung Diseases: Pathological processes involving any part of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "But melatonin treatment was found more efficient than SMT treatment." | 1.39 | The protective effect of melatonin and S-methylisothiourea treatments in nitrogen mustard induced lung toxicity in rats. ( Aydin, I; Kenar, L; Korkmaz, A; Kunak, ZI; Macit, E; Onguru, O; Turel, S; Uysal, B; Yaman, H; Yaren, H, 2013) |
| " Prospective pharmacokinetic studies to devise a rational dosing strategy for vinblastine in patients receiving ritonavir/lopinavir are warranted." | 1.38 | Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. ( Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS, 2012) |
| "The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level." | 1.36 | Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. ( Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010) |
| "Therefore, 126 patients suffering from Hodgkin's disease were investigated after a follow-up of at least 5 years from the completion of the combined treatment." | 1.35 | Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. ( Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Villani, M; Viviani, S, 2009) |
| "Melatonin was administered intraperitoneally with two different doses (20mg/kg or 40mg/kg) beginning 1h before HN2 application and continued every 12h for six replications." | 1.34 | Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. ( Korkmaz, A; Kurt, B; Oter, S; Reiter, RJ; Topal, T; Ucar, M; Yaren, H, 2007) |
| "Although most patients with Hodgkin's disease refractory to MOPP treatment will respond to either ABVD or B-CAVe chemotherapy, subsequent long-term disease-free survival is unusual." | 1.27 | Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. ( Harker, WG; Kushlan, P; Rosenberg, SA, 1984) |
| "Procarbazine may have been the responsible agent." | 1.26 | Diffuse pulmonary disease after therapy with nitrogen mustard, vincristine, procarbazine, and prednisone. ( Armstrong, JD; Farney, RJ; Hammer, S; Morris, AH, 1977) |
| "A case of nodular sclerosis Hodgkin's disease, stage IVB, with lung involvement and hypertrophic pulmonary osteoarthropathy (HPOA), was treated with quadruple cytotoxic chemotherapy." | 1.26 | Hypertrophic pulmonary osteoarthropathy in Hodgkin's disease: reversal with chemotherapy. ( Atkinson, MK; McElwain, TJ; Peckham, MJ; Thomas, PP, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (53.57) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 5 (17.86) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Macit, E | 1 |
| Yaren, H | 3 |
| Aydin, I | 1 |
| Kunak, ZI | 1 |
| Yaman, H | 1 |
| Onguru, O | 1 |
| Uysal, B | 1 |
| Korkmaz, A | 3 |
| Turel, S | 1 |
| Kenar, L | 1 |
| Villani, F | 3 |
| Busia, A | 2 |
| Villani, M | 1 |
| Laffranchi, A | 2 |
| Viviani, S | 3 |
| Bonfante, V | 3 |
| Ezzat, HM | 1 |
| Cheung, MC | 1 |
| Hicks, LK | 1 |
| Boro, J | 1 |
| Montaner, JS | 1 |
| Lima, VD | 1 |
| Harris, M | 1 |
| Leitch, HA | 1 |
| Evens, AM | 1 |
| Hong, F | 1 |
| Gordon, LI | 1 |
| Fisher, RI | 1 |
| Bartlett, NL | 1 |
| Connors, JM | 1 |
| Gascoyne, RD | 1 |
| Wagner, H | 1 |
| Gospodarowicz, M | 1 |
| Cheson, BD | 1 |
| Stiff, PJ | 1 |
| Advani, R | 1 |
| Miller, TP | 1 |
| Hoppe, RT | 2 |
| Kahl, BS | 1 |
| Horning, SJ | 1 |
| RAO, SR | 1 |
| MENON, ND | 1 |
| SMITH, ME | 1 |
| HUNEYCUTT, HC | 1 |
| ANDERSON, WR | 1 |
| HENDRY, WS | 1 |
| HOCKMAN, RP | 1 |
| MARK, JB | 1 |
| Mollaoglu, H | 1 |
| Kurt, B | 2 |
| Oter, S | 2 |
| Topal, T | 2 |
| Karayilanoglu, T | 1 |
| Wang, GQ | 1 |
| Xia, ZF | 1 |
| Diehl, V | 1 |
| Fuchs, M | 1 |
| Ucar, M | 1 |
| Reiter, RJ | 1 |
| BEN-ASHER, S | 1 |
| BROWN, A | 1 |
| DAVIS, LJ | 1 |
| Harker, WG | 1 |
| Kushlan, P | 1 |
| Rosenberg, SA | 1 |
| Raez, LE | 1 |
| Temple, JD | 1 |
| Saldana, M | 1 |
| Bossi, G | 1 |
| Cerveri, I | 1 |
| Volpini, E | 1 |
| Corsico, A | 1 |
| Baio, A | 1 |
| Corbella, F | 1 |
| Klersy, C | 1 |
| Arico, M | 1 |
| Farney, RJ | 1 |
| Morris, AH | 1 |
| Armstrong, JD | 1 |
| Hammer, S | 1 |
| Atkinson, MK | 1 |
| McElwain, TJ | 1 |
| Peckham, MJ | 1 |
| Thomas, PP | 1 |
| Allavena, C | 1 |
| Conroy, T | 1 |
| Aletti, P | 1 |
| Bey, P | 1 |
| Lederlin, P | 1 |
| Shanley, DJ | 1 |
| Lerud, KS | 1 |
| Luetkehans, TJ | 1 |
| Santoro, A | 1 |
| Bonadonna, G | 1 |
| Valagussa, P | 1 |
| Zucali, R | 1 |
| Pagnoni, AM | 1 |
| Musumeci, R | 1 |
| Crippa, F | 1 |
| Watchie, J | 1 |
| Coleman, CN | 1 |
| Raffin, TA | 1 |
| Cox, RS | 1 |
| Raubitschek, AA | 1 |
| Fahey, T | 1 |
| Van Kessel, A | 1 |
| Albertine, KH | 1 |
| Rowland, KM | 1 |
| Murthy, A | 1 |
| Kawano, T | 1 |
| Mori, S | 1 |
| Cybulsky, M | 1 |
| Burger, R | 1 |
| Ballin, A | 1 |
| Cutz, E | 1 |
| Bryan, AC | 1 |
| Laughlin, MJ | 1 |
| Wild, L | 1 |
| Nickerson, PA | 1 |
| Matalon, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease[NCT00003389] | Phase 3 | 854 participants (Actual) | Interventional | 1999-06-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival is defined as the time from randomization to death or last known alive. The 5-year survival rate is the probability a patient survives 5 years. (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.88 |
| Arm B (Stanford V) | 0.88 |
"Failure-free survival is defined as the time from randomization to the earlier of progression/relapse or death. The 5-year failure-free survival is the probability a patient is failure-free and survives 5 years.~Progression is defined as an increase in size of 25% of the sum of the products of the pretreatment measurements or appearance of new lesions. Significant enlargement of the liver or spleen is evidence of progression. A significant increase in size is defined as > 2.0 cm in distance between costal margin and the inferior margin of either organ.~Relapse is defined as the re-appearance of any clinical evidence of Hodgkin's disease in a patient who has had a complete response. Relapse for partial responders is defined as progressive disease relative to disease status during the partial remission." (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (ABVD) | 0.74 |
| Arm B (Stanford V) | 0.71 |
Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years
| Intervention | participants (Number) |
|---|---|
| Arm A (ABVD) | 15 |
| Arm B (Stanford V) | 19 |
2 reviews available for mechlorethamine and Lung Diseases
| Article | Year |
|---|---|
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 2007 |
Hodgkin's disease: long-term effects of therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Brain; Female; Genitalia, Fem | 1986 |
2 trials available for mechlorethamine and Lung Diseases
| Article | Year |
|---|---|
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dac | 2013 |
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined | 1987 |
24 other studies available for mechlorethamine and Lung Diseases
| Article | Year |
|---|---|
The protective effect of melatonin and S-methylisothiourea treatments in nitrogen mustard induced lung toxicity in rats.
Topics: Animals; Chemical Warfare Agents; Interleukin-1beta; Isothiuronium; Lung; Lung Diseases; Male; Mechl | 2013 |
Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiovascular Diseases; Com | 2009 |
Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiovascular Diseases; Com | 2010 |
Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomy | 2012 |
A CASE OF MULTIPLE MYELOMA TREATED WITH OESTROGENS.
Topics: Cortisone; Estrogens; Ethinyl Estradiol; Lung Diseases; Lung Neoplasms; Mechlorethamine; Multiple My | 1963 |
RETINAL INVOLVEMENT IN ADULT CYTOMEGALIC INCLUSION DISEASE.
Topics: Adult; Choroid; Cryptococcosis; Cyclophosphamide; Cytomegalovirus Infections; Eye Manifestations; Ge | 1964 |
PNEUMOCYSTIS CARINII PNEUMONIA. CASE STUDIES WITH ELECTRON MICROSCOPY.
Topics: Chlorambucil; Chloramphenicol; Cytomegalovirus Infections; Diagnosis, Differential; Digoxin; Electro | 1964 |
EFFECT OF BRONCHIAL ARTERIAL INFUSION OF MECHLORETHAMINE ON PULMONARY STRUCTURE IN THE EXPERIMENTAL ANIMAL.
Topics: Abscess; Axillary Artery; Brachial Artery; Carcinoma; Carcinoma, Bronchogenic; Dogs; Humans; Lung; L | 1964 |
Lung toxicity of nitrogen mustard may be mediated by nitric oxide and peroxynitrite in rats.
Topics: Alkylating Agents; Animals; Antioxidants; Azoles; Guanidines; Isoindoles; Lung Diseases; Male; Mechl | 2007 |
Tissue injury by hot fluid containing nitrogen mustard.
Topics: Accidents, Occupational; Adult; Burns, Chemical; Chemical Warfare Agents; Digestive System Diseases; | 2007 |
Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard.
Topics: Animals; Antioxidants; Biomarkers; Chemical Warfare Agents; Disease Models, Animal; Dose-Response Re | 2007 |
Nitrogen mustard therapy; the use of methyl bis (B chloroethyl) amine hydrochloride in Hodgkin's disease, leukemia, lymphosarcoma and cancer of the lung.
Topics: Amines; Ethylamines; Hodgkin Disease; Humans; Leukemia; Lung Diseases; Lung Neoplasms; Lymphoma; Lym | 1949 |
Nitrogen mustard therapy in reticuloses and pulmonary neoplasm; a report on 44 cases.
Topics: Disease; Ethylamines; Lung Diseases; Lung Neoplasms; Mechlorethamine; Mononuclear Phagocyte System; | 1949 |
Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1984 |
Successful treatment of lymphomatoid granulomatosis using cyclosporin-A after failure of intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Combined Modality Therap | 1996 |
Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Comb | 1997 |
Diffuse pulmonary disease after therapy with nitrogen mustard, vincristine, procarbazine, and prednisone.
Topics: Adult; Biopsy; Drug Hypersensitivity; Female; Hodgkin Disease; Humans; Lung Diseases; Mechlorethamin | 1977 |
Hypertrophic pulmonary osteoarthropathy in Hodgkin's disease: reversal with chemotherapy.
Topics: Adult; Antineoplastic Agents; Drug Therapy, Combination; Hodgkin Disease; Humans; Lung Diseases; Mal | 1976 |
Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Exerci | 1992 |
Development of pulmonary histiocytosis X after chemotherapy for Hodgkin disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Fem | 1990 |
Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Body Composition; Elec | 1987 |
Lung injury and neutrophil density during air embolization in sheep after leukocyte depletion with nitrogen mustard.
Topics: Animals; Arteries; Capillaries; Cell Count; Embolism, Air; Endothelium; Leukocyte Count; Leukocytes; | 1988 |
Effect of granulocyte depletion in a ventilated surfactant-depleted lung.
Topics: Animals; Epithelium; Granulocytes; Leukocyte Count; Lung Diseases; Mechlorethamine; Pulmonary Gas Ex | 1987 |
Effects of hyperoxia on alveolar permeability of neutropenic rabbits.
Topics: Agranulocytosis; Animals; Epithelium; Lung Diseases; Mechlorethamine; Neutropenia; Neutrophils; Oxyg | 1986 |